Mantle Cell Lymphoma

CLINICAL_TRIALS trial_result · 2014-07-21

Clinical Trial Update: Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma [Phase 2]

Phase 2 trial update for untreated mantle cell lymphoma using Hyper-CVAD/rituximab; study completed with results posted in 2014.

CLINICAL_TRIALS trial_result · 2014-07-18

Clinical Trial Update: Intensive Induction Therapy Followed by High Dose Chemo and BM Transplant for Mantle Cell Lymphoma [Phase 2]

Phase 2 clinical trial update evaluating intensive induction therapy followed by high-dose chemotherapy and bone marrow transplant for Mantl…

CLINICAL_TRIALS trial_result · 2014-07-01

Clinical Trial Update: Imexon for Relapsed Follicular and Aggressive Lymphomas [Phase 2]

Phase 2 clinical trial results for imexon in relapsed follicular lymphoma and various aggressive B-cell lymphomas have been completed with r…

CLINICAL_TRIALS trial_result · 2014-05-22

Clinical Trial Update: Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma [Phase 2]

Phase 2 trial evaluating fludarabine, mitoxantrone, and rituximab in mantle cell lymphoma has been terminated. The study NCT00183989 is no l…

CLINICAL_TRIALS trial_result · 2014-05-20

Clinical Trial Update: Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma [Phase 2]

A Phase 2 trial evaluating Velcade (bortezomib) in combination with rituximab for relapsed/refractory mantle cell lymphoma and follicular no…

CLINICAL_TRIALS trial_result · 2014-05-19

Clinical Trial Update: Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer [Phase 3]

Phase 3 trial evaluating total-body irradiation with or without fludarabine phosphate followed by donor stem cell transplant in hematologic …

CLINICAL_TRIALS trial_result · 2014-05-09

Clinical Trial Update: SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL) [Phase 2]

Phase 2 trial evaluating SDX-105 in combination with Rituxan for relapsed indolent or mantle cell Non-Hodgkin's Lymphoma has completed.

CLINICAL_TRIALS trial_result · 2014-04-29

Clinical Trial Update: MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia [Phase 1]

Phase 1 study of MK-2206 in pediatric patients with recurrent or refractory solid tumors or leukemias has completed.

CLINICAL_TRIALS trial_result · 2014-04-28

Clinical Trial Update: Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study [Phase 3]

Phase 3 trial comparing bendamustine plus rituximab to R-CVP or R-CHOP in first-line advanced indolent non-Hodgkin's lymphoma or mantle cell…

CLINICAL_TRIALS trial_result · 2014-04-24

Clinical Trial Update: Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma [Phase 2]

A Phase II trial evaluating chemotherapy followed by Zevalin (ibritumomab tiuxetan) for relapsed mantle cell lymphoma has completed.

CLINICAL_TRIALS trial_result · 2014-04-08

Clinical Trial Update: Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma [Phase 2]

Phase 2 trial evaluating iodine-131 labeled anti-B1 antibody with CHOP for untreated mantle cell lymphoma has completed with results posted.

CLINICAL_TRIALS trial_result · 2014-04-04

Clinical Trial Update: Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) [Phase 3]

Phase 3 trial evaluating the effect of bendamustine in combination with rituximab on QT interval in patients with advanced indolent non-Hodg…

CLINICAL_TRIALS trial_result · 2014-04-03

Clinical Trial Update: CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma [Phase 2]

Phase 2 study of temsirolimus (CCI-779) for recurrent mantle cell lymphoma has completed.

CLINICAL_TRIALS trial_result · 2014-04-01

Clinical Trial Update: Bortezomib in Treating Patients With Lymphoproliferative Disorders [Phase 2]

Phase 2 study of bortezomib in recurrent lymphoproliferative disorders, including follicular lymphoma and mantle cell lymphoma; results were…

CLINICAL_TRIALS trial_result · 2014-03-11

Clinical Trial Update: CART-19 Immunotherapy in Mantle Cell Lymphoma [Phase 1, Phase 2]

This clinical trial update reports a CART-19 immunotherapy being evaluated in Phase 1/2 for Mantle Cell Lymphoma, with the trial status curr…

CLINICAL_TRIALS trial_result · 2014-03-05

Clinical Trial Update: Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat [Phase 1]

This is a Phase 1b trial update of AMG 655 in combination with bortezomib or vorinostat for lymphomas, including Hodgkin lymphoma and variou…

CLINICAL_TRIALS trial_result · 2014-02-27

Clinical Trial Update: Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma [Phase 2]

This update reports results from a Phase 2 trial of ixabepilone in relapsed or refractory aggressive non-Hodgkin lymphoma across multiple su…

CLINICAL_TRIALS trial_result · 2014-02-24

Clinical Trial Update: Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas [Phase 1]

Phase 1 trial evaluating the combination of tanespimycin and bortezomib in adults with advanced solid tumors or lymphomas; the study was ter…

CLINICAL_TRIALS trial_result · 2014-02-20

Clinical Trial Update: Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]

Phase 2 trial evaluating bortezomib and lenalidomide in relapsed or refractory mantle cell lymphoma has completed with results posted.

CLINICAL_TRIALS trial_result · 2014-02-11

Clinical Trial Update: CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia [Phase 2]

A Phase 2 clinical trial evaluating CCI-779 (temsirolimus) in patients with recurrent or refractory B-cell non-Hodgkin lymphoma or chronic l…

CLINICAL_TRIALS trial_result · 2014-01-28

Clinical Trial Update: Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma [Phase 2]

Phase 2 trial evaluating a regimen of Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium-90 ibritumomab tiuxetan…

CLINICAL_TRIALS trial_result · 2014-01-22

Clinical Trial Update: CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]

Phase 2 results for the combination of temsirolimus (CCI-779) and rituximab in relapsed or refractory non-Hodgkin lymphoma have been reporte…

CLINICAL_TRIALS trial_result · 2014-01-03

Clinical Trial Update: A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy [EARLY_Phase 1]

A Phase 1 study evaluating the safety and tolerability of combining sirolimus with Hyper-CVAD chemotherapy in adults with lymphoid malignanc…

CLINICAL_TRIALS trial_result · 2013-12-18

Clinical Trial Update: Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell Lymphoma [Phase 2]

A Phase 2 study evaluating chemotherapy with or without Rituximab in mantle cell lymphoma has completed. The update notes the trial compared…

CLINICAL_TRIALS trial_result · 2013-09-30

Clinical Trial Update: Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia [Phase 1]

Phase 1 trial evaluating bortezomib and fludarabine with or without rituximab in relapsed or refractory indolent non-Hodgkin lymphoma or chr…

Top drugs studied for this disease